Newsroom | 49094 results

DUBLIN--(BUSINESS WIRE)--The "Spondyloarthritis (Spondyloarthropathy) - Global Clinical Trials Review, 2025" clinical trials report has been added to ResearchAndMarkets.com's offering. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for i...

DUBLIN--(BUSINESS WIRE)--The "Lupus Nephritis - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on num...

DUBLIN--(BUSINESS WIRE)--The "IgA Nephropathy (Berger's Disease) - Global Clinical Trials Review, 2025" clinical trials report has been added to ResearchAndMarkets.com's offering. This report provides top line data relating to the clinical trials on IgA Nephropathy (Berger's Disease). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), ph...

TORONTO--(BUSINESS WIRE)--New data from Phoenix found 38% of Canadians don’t consider their health and wellness goals to be enough of a reason to book a doctor’s appointment....

DUBLIN--(BUSINESS WIRE)--The "AI & ML in Clinical Trials: Fundamentals, Applications, and Regulatory Aspects (May 11, 2026)" training has been added to ResearchAndMarkets.com's offering. Artificial Intelligence (AI) and Machine Learning (ML) are rapidly reshaping the clinical trials landscape, driving innovation in how research is designed, conducted and evaluated. This course is aimed at anyone working in clinical research, clinical operations, data management, regulatory and compliance, a...

SAN DIEGO--(BUSINESS WIRE)--Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary LEADS® drug discovery platform, announced today it has been awarded a research grant from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH), to further advance its data-driven drug discovery capabilities. Omics technologies enable comprehensive characterization of cellular systems. This means phenot...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of John P. “Jack” Kenny to its Board of Directors....

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has entered into a strategic partnership agreement with a global digital engineering and software development services firm. This engagement is a central component of the Company’s broader operating model transformation, designed to improve execution, increase development predictabil...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) it will discontinue the trial to focus resources on clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors. The...

HOUSTON--(BUSINESS WIRE)--PathoCare Holdings, Inc.—the parent company of medical diagnostics innovator PathoCare, LLC, a leader in Lab-on-a-Chip non-invasive Point-of-Care diagnostics—today announced that it has received a private, third-party tendered offer involving the secondary purchase of shares from existing shareholders, reflecting an implied company valuation of approximately $1.75 billion. The tendered offer represents a continuation of PathoCare Holdings’ capital markets evolution fol...